Page last updated: 2024-10-31

nefazodone and Weight Gain

nefazodone has been researched along with Weight Gain in 3 studies

nefazodone: may be useful as an opiate adjunct

Weight Gain: Increase in BODY WEIGHT over existing weight.

Research Excerpts

ExcerptRelevanceReference
"Anecdotal reports have suggested that the long-term use of selective serotonin reuptake inhibitors (SSRIs) may be associated with significant weight gain, sexual dysfunction, drug interactions, and discontinuation symptoms."2.41Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine. ( Gupta, S; Masand, PS, 2002)
"Nefazodone treatment was associated with fewer side effects than were the control drugs."2.39The safety profile of nefazodone. ( Kaplita, SB; Marcus, RN; Roberts, DL; Robinson, DS; Seminara, JA; Smith, JM; Stringfellow, JC, 1996)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (33.33)18.2507
2000's2 (66.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Masand, PS1
Gupta, S1
Robinson, DS1
Roberts, DL1
Smith, JM1
Stringfellow, JC1
Kaplita, SB1
Seminara, JA1
Marcus, RN1
Sussman, N1
Ginsberg, DL1
Bikoff, J1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effects of a High Eicosapentaenoic Acid Multinutrient Supplement on Measures of Stress, Anxiety and Depression in Young Adults: a Randomised, Double-blind, Placebo-controlled Trial.[NCT04844034]94 participants (Anticipated)Interventional2022-04-19Recruiting
Effects of a Tissue Selective Estrogen Complex (TESC) on Depression and the Neural Reward System in the Perimenopause[NCT03740009]Phase 420 participants (Actual)Interventional2019-01-02Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Frontostriatal Reactivity to Reward During MID fMRI Task

"The primary outcome measure is functional magnetic resonance imaging (fMRI) data collected during a Monetary Incentive Delay (MID) Task. All participants will complete the fMRI Monetary Incentive Delay (MID) task at baseline and at 3 weeks. During the task, participants need to select the correct response during win and lose conditions by pressing a button on a button box in the MRI. Participant's blood-oxygen-level dependent (BOLD) activation response (A measurement of oxygen level that is released to neurons since areas of the brain that are thought to be more active or involved in certain tasks require more oxygen to perform the tasks.) is measured while they performed the task in MRI scanner." (NCT03740009)
Timeframe: Baseline to 3 weeks

Interventionpercent signal change (Mean)
Caudate BaselineCaudate PosttreatmentNucleus Accumbens BaselineNucleus Accumbens PosttreatmentPutamen BaselinePutamen Posttreatment
Perimenopausal Women, Depressed.0704.0475.0623.0280.0399.0408

Depressive Symptoms as Measured by the MASQ-AD

The second primary outcome measure uses the Mood and Anxiety Symptoms Questionnaire - Anhedonic Depression Scale (MASQ-AD) to examine symptom change. All participants will complete the MASQ-AD at each study visit, which measures their current symptoms of depression and anxiety. Scores range from 22 to 110 with lower scores reflecting a better outcome. (NCT03740009)
Timeframe: Baseline, week 2, week 3, week 4 (post treatment)

Interventionscore on a scale (Mean)
Baseline Week 1Week 2Week 3Post Treatment Week 4
Perimenopausal Women, Depressed72.162.457.254.5

Reviews

3 reviews available for nefazodone and Weight Gain

ArticleYear
Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine.
    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 2002, Volume: 14, Issue:3

    Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Drug Interactions; Humans; Mians

2002
Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine.
    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 2002, Volume: 14, Issue:3

    Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Drug Interactions; Humans; Mians

2002
Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine.
    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 2002, Volume: 14, Issue:3

    Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Drug Interactions; Humans; Mians

2002
Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine.
    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 2002, Volume: 14, Issue:3

    Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Drug Interactions; Humans; Mians

2002
The safety profile of nefazodone.
    The Journal of clinical psychiatry, 1996, Volume: 57 Suppl 2

    Topics: Adolescent; Adult; Age Factors; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agent

1996
Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials.
    The Journal of clinical psychiatry, 2001, Volume: 62, Issue:4

    Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Body Weight; Controlled

2001